Delair Acquires Key Airware Assets to Expand its Leadership in Commercial Drone Industry
Delair, a leading supplier of commercial drone solutions, today announced an agreement to acquire the key assets of Airware, a developer of innovative software analytics tools for drone-based data. The acquisition brings Delair leading edge technology assets, including a proven software solution, a highly skilled engineering and customer success team in Paris, and an installed base of customers and dealers worldwide. The acquisition accelerates Delair’s global growth and broadens its end-to-end solution for the commercial UAV market. Financial terms were not disclosed.
“The acquisition signals a new period of growth and product line expansion by Delair. With the integration of Airware’s complementary technology, we have significantly strengthened our position as the leading provider of drone-based business intelligence globally. This strategic development further enhances our offer which enables the digital transformation of enterprises in the key industries we serve,” said Michaël de Lagarde, co-founder and CEO of Delair.
Major synergies between two pioneering drone companies
The addition of Airware's assets will expand Delair’s presence in the United States, as well as in key industrial markets.
Founded in 2011 in California, Airware has developed a successful software offering and its cloud-based solution has been adopted by large companies in the construction, mining and insurance industries. Airware (and previously Redbird) developed its solution together with Caterpillar. Caterpillar dealers covering more than 50 countries have provided the Airware software to their customers to improve productivity and safety on mines, quarries, and construction sites.
Airware’s technology complements the product line from Delair, which is recognized as one of the world's leading pioneers in commercial drone solutions, especially for beyond visual line of sight (BVLOS) operations. Delair has focused on end-to-end solutions since its inception in 2011, including fixed-wing drones, cloud-based data processing and analysis, local customer support and custom consulting services. In September 2018, Delair closed a round of B-Series financing with Intel Capital to accelerate the development of its software offering, and the Airware acquisition supports that strategy. The company, which now has more than 180 employees worldwide, supports customers in a wide range of industries such as mining, construction, energy, utilities, oil and gas, transportation, security and agriculture.
Continuity of Service for Airware Customers and Dealers
The agreement between the two companies includes a business continuity plan to ensure existing Airware customers and dealers receive world class support and service, as well as upgrades as needed.
“Airware played a pivotal role in enabling enterprises to leverage drone technology and powerful analytics to improve productivity, mitigate risks, and take workers out of harm’s way. As we looked for a partner, we were impressed by Delair’s vision and all the synergies that exist between our technologies and our views of the market. The drone industry is maturing fast and customers are now looking for comprehensive, end-to-end solutions. Airware’s advanced data management and data analysis tools will be highly complementary with Delair’s existing solutions. This will greatly benefit all our customers, who are using drone technologies to improve their operations. We are proud that our technology and much of our team lives on as part of the market leader, Delair,” said Sasha Pesic, CEO of Airware.
Redbird technology adds skilled talents to data analytics solution
In 2016 Airware acquired Redbird, a software development operation based in Paris. Founded in 2013, Redbird was a pioneer in software solutions for drone data analytics, particularly for mining, quarries and construction. The Redbird team will continue to be based in Paris and be integrated with Delair’s engineering and customer success operations, working on new data-based services as well as applying leading-edge artificial intelligence to drone data collection and analysis.
“We are very excited to see our team joining Delair. There’s a great fit as this will form a comprehensive solution with hardware, advanced software, and customized services. Optimized analytics is the key piece of software that enterprise companies need to scale their drone program. We look forward to leveraging our unique capabilities in machine learning and commercializing them with Delair,” said de Maistre, co-founder and former CEO of Redbird, who will lead software channel sales efforts at Delair.
About Delair: www.delair.aero and on twitter @DelairTech
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Game of Thrones Winter is Coming™ Launches Worldwide25.3.2019 23:00:00 CET | Pressemelding
Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi
Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA25.3.2019 23:00:00 CET | Pressemelding
Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W
bluebird bio Statement on European Regulatory Status of LentiGlobin™25.3.2019 22:40:00 CET | Pressemelding
A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 20:30:00 CET | Pressemelding
Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in
AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 19:50:00 CET | Pressemelding
Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin
Historic Partnership between the Weizmann Institute of Science and Institut Curie25.3.2019 16:54:00 CET | Pressemelding
On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics. Collaborative research programs This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot.